Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

MET-Oncogenic and JAK2-Inactivating Alterations Are Independent Factors That Affect Regulation of PD-L1 Expression in Lung Cancer.

Saigi M, Alburquerque-Bejar JJ, Mc Leer-Florin A, Pereira C, Pros E, Romero OA, Baixeras N, Esteve-Codina A, Nadal E, Brambilla E, Sanchez-Cespedes M.

Clin Cancer Res. 2018 Sep 15;24(18):4579-4587. doi: 10.1158/1078-0432.CCR-18-0267. Epub 2018 Jun 13.

PMID:
29898990
2.

Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.

Saigi M, McLeer-Florin A, Pros E, Nadal E, Brambilla E, Sanchez-Cespedes M.

Clin Transl Oncol. 2018 Jul;20(7):881-888. doi: 10.1007/s12094-017-1799-7. Epub 2017 Nov 14.

PMID:
29139039
3.

Clinical relevance of histologic subtypes in locally advanced esophageal carcinoma treated with pre-operative chemoradiotherapy: Experience of a monographic oncologic centre.

Saigí M, Oliva M, Aliste L, Calvo M, Hormigo G, Serra Ò, Boladeras A, Farran L, Robles J, Creus G, Paúles MJ, Gornals JB, de Lama E, Borràs JM, Sala N, Galán M.

PLoS One. 2017 Sep 20;12(9):e0184737. doi: 10.1371/journal.pone.0184737. eCollection 2017.

4.

Cetuximab as treatment for head and neck cancer patients with a previous liver transplant: report of two cases.

Holguin F, Rubió-Casadevall J, Saigi M, Marruecos J, Taberna M, Tobed M, Maños M, Mesía R.

J Chemother. 2017 Oct;29(5):310-313. doi: 10.1080/1120009X.2016.1187360. Epub 2016 Jul 5.

PMID:
27380218
5.

A Novel Epigenetic Signature for Early Diagnosis in Lung Cancer.

Diaz-Lagares A, Mendez-Gonzalez J, Hervas D, Saigi M, Pajares MJ, Garcia D, Crujerias AB, Pio R, Montuenga LM, Zulueta J, Nadal E, Rosell A, Esteller M, Sandoval J.

Clin Cancer Res. 2016 Jul 1;22(13):3361-71. doi: 10.1158/1078-0432.CCR-15-2346. Epub 2016 Feb 3.

Supplemental Content

Support Center